

Name of Journal: *World Journal of Gastroenterology*

Manuscript NO: 55265

Manuscript Type: ORIGINAL ARTICLE

Retrospective Study

Efficacy and safety of lenvatinib for patients with advanced hepatocellular carcinoma: A retrospective, real-world study conducted in China

Wang DX *et al.* Lenvatinib for HCC in China

Dong-Xu Wang, Xu Yang, Jian-Zhen Lin, Yi Bai, Jun-Yu Long, Xiao-Bo Yang,
Samuel Seery, Hai-Tao Zhao

Abstract

Match Overview

Rank	Source	Words	Similarity
1	Crossref	83 words Takeshi Hatanaka, Satoru Kakizaki, Tamon Nagashima, Masashi Namikawa et al. "Analyses of objective respons	2%
2	Internet	42 words crawled on 22-Nov-2018 www.esmo.org	1%
3	Internet	41 words crawled on 29-Jan-2020 www.mdpi.com	1%
4	Internet	32 words crawled on 19-Apr-2020 www.dovepress.com	1%
5	Crossref Posted Content	24 words Tetsu Tomonari, Yasushi Sato, Hironori Tanaka, Takahiro Tanaka et al. "Therapeutic Efficacy and Safety of Lenvat	<1%
6	Crossref	21 words Kazuki Maesaka, Ryotaro Sakamori, Ryoko Yamada, Aya ko Urabe et al. "Therapeutic efficacy of lenvatinib in hej ...	<1%
7	Internet	21 words crawled on 05-Mar-2020 cslide.ctimeetingtech.com	<1%
8	Internet	14 words crawled on 26-May-2020 ar.iiarjournals.org	<1%
9	Internet	14 words crawled on 03-Jun-2020 ilca-online.org	<1%
10	Internet	13 words crawled on 28-Mar-2019 link.springer.com	<1%
11	Internet	13 words crawled on 28-Mar-2020 onlinelibrary.wiley.com	<1%

Efficacy and Safety of Lenvatinib for Patients with Advanc



ALL

IMAGES

VIDEOS

20,400 Results

Any time ▾

[Safety and efficacy profile of lenvatinib in cancer ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5190117>

Jul 12, 2016 · **Study** characteristics. Of the studies that were included in the final analysis, 3 studies were based on thyroid cancer **patients**, 5 evaluated **advanced** solid tumors, 1 evaluated non-small-cell lung cancer, 1 was based on melanoma, 2 were performed on metastatic renal cell **carcinoma**, 1 was on **advanced hepatocellular carcinoma** and 1 on healthy adults.

Cited by: 21

Author: Chenjing Zhu, Xuele Ma, Yuanyuan Hu, ...

Publish Year: 2016

[Complete response to the combination of Lenvatinib and ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6839182>

Nov 08, 2019 · Background. **Hepatocellular carcinoma** (HCC) is the fifth leading cause of cancer death in the United States with a 5-year survival rate of 18% for all stages [] and its incidence rate is rising faster than that of any other cancer in both men and women [].Rates of both incidence (18.3 per 100,000) and mortality (17.1 per 100,000) are 2 to 3 times higher in **China** than those estimated in most ...

Author: Zhaonan Liu, Xingjie Li, Xuequn He, Y... **Publish Year:** 2019



ALL

IMAGES

VIDEOS

29,600 Results

Any time ▾

[The Efficacy and Safety of Apatinib Treatment for Patients ...](#)

<https://www.ncbi.nlm.nih.gov> › pmc › articles › PMC6096375

Jul 16, 2018 · **Patients Characteristics.** A total of 32 patients with refractory or relapsed liver cancer were included in this **retrospective study**. Patient characteristics at baseline were summarized in Table 1. 1. 22 patients (69%) were male and 24 patients (75%) were older than 65. Most of the patients (78%) were diagnosed as **hepatocellular carcinoma**.

Cited by: 4

Author: Liu Zhen, Chen Jiali, Fang Yong, Xufeng ...

Publish Year: 2018

[Efficacy and safety of lenvatinib \(LEN\) in Korean patients ...](#)

<https://www.researchgate.net> › publication › 339033970...

Efficacy and safety of lenvatinib (LEN) in Korean patients (pts) with advanced hepatocellular carcinoma (aHCC): Multicenter retrospective analysis.

[Clinical features of lenvatinib for unresectable ...](#)

<https://www.ncbi.nlm.nih.gov> › pmc › articles › PMC6346240

Dec 21, 2018 · 1. INTRODUCTION. For treatment of unresectable **hepatocellular carcinoma** (u-HCC), tyrosine kinase inhibitors (TKIs), such as sorafenib (SOR) 1, 2 and regorafenib (REG), 3, 4 have been introduced. SOR was developed as a first-line agent for u-HCC, while REG is used as second-line therapy in patients who show good tolerability and progressive disease (PD) with SOR.

Cited by: 21

Author: Atsushi Hiraoka, Takashi Kumada, Kazuy...

Publish Year: 2019

[\(PDF\) Efficacy and Safety of apatinib in patients with ...](#)

<https://www.researchgate.net> › publication › 322566395...

The purpose of this study is to investigate the **efficacy and safety** of apatinib in patients with advanced colorectal cancer for whom at least two lines of prior chemotherapy had failed.

[Clinical features of lenvatinib for unresectable ...](#)

<https://www.onlinelibrary.wiley.com> › doi › full › 10.1002 › cam4.1909

Dec 21, 2018 · 1 INTRODUCTION. For treatment of unresectable **hepatocellular carcinoma** (u-HCC), tyrosine kinase inhibitors (TKIs), such as sorafenib (SOR) 1, 2 and regorafenib (REG), 3, 4 have been introduced. SOR was developed as a first-line agent for u-HCC, while REG is used as second-line



30,000 Results Any time ▾

[The Efficacy and Safety of Apatinib Treatment for Patients ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6096375>

Jul 16, 2018 · **Patients** Characteristics. A total of 32 **patients** with refractory or relapsed liver cancer were included in this **retrospective study**. **Patient** characteristics at baseline were summarized in Table Table1. 1. 22 **patients** (69%) were male and 24 **patients** (75%) were older than 65. Most of the **patients** (78%) were diagnosed as **hepatocellular carcinoma**.

Cited by: 4 **Author:** Liu Zhen, Chen Jiali, Fang Yong, Xufeng ...

Publish Year: 2018

[Clinical features of lenvatinib for unresectable ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346240>

Dec 21, 2018 · 1. INTRODUCTION. For treatment of unresectable **hepatocellular carcinoma** (u-HCC), tyrosine kinase inhibitors (TKIs), such as sorafenib (SOR) 1, 2 and regorafenib (REG), 3, 4 have been introduced. SOR was developed as a first-line agent for u-HCC, while REG is used as second-line therapy in **patients** who show good tolerability and progressive disease (PD) with SOR.

Cited by: 21 **Author:** Atsushi Hiraoka, Takashi Kumada, Kazuy...

Publish Year: 2019

[Efficacy and safety of lenvatinib \(LEN\) in Korean patients ...](#)

<https://www.researchgate.net/publication/339033970...>

Request PDF | **Efficacy and safety of lenvatinib** (LEN) in Korean **patients** (pts) **with advanced hepatocellular carcinoma** (aHCC): Multicenter **retrospective** analysis. | 490 Background: LEN has ...

[\(PDF\) Efficacy and Safety of apatinib in patients with ...](#)

<https://www.researchgate.net/publication/322566395...>

Efficacy and Safety of apatinib in **patients** with intermediate/**advanced hepatocellular carcinoma**: A prospective observation **study** Article (PDF Available) in *Medicine* 97(3):e9704 · January 2018 ...

[Clinical features of lenvatinib for unresectable ...](#)